Recursion Pharmaceuticals Appoints Dr. Robert Hershberg as New Board Chair

Recursion (NASDAQ: RXRX) has appointed Dr. Robert Hershberg, M.D., Ph.D., as the new chair of the board, effective at the end of the current term. Dr. Hershberg, who has been a member of the board since May 2020, brings over 25 years of experience as a physician, scientist, and entrepreneur to the role.

Dr. Hershberg's extensive background includes serving as the CEO, president, and chair of the board of Hillevax, Inc., a biopharmaceutical company focused on novel vaccine candidates. He has also been a venture partner at Frazier Healthcare Partners since 2020. Prior to this, he held the position of executive vice president and head of business development and global alliances at Celgene, and served as the chief scientific officer from January 2016 to March 2020. Dr. Hershberg co-founded Ventirx Pharmaceuticals, where he was the CEO until its acquisition by Celgene in February 2017.

As a member of the board of directors of Adaptive Biotechnologies and the scientific advisory board of Danaher Corporation, Dragonfly Therapeutics, Skyhawk Therapeutics, and the Institute for Protein Design at the University of Washington, Dr. Hershberg's expertise spans various facets of the biopharmaceutical industry.

Chris Gibson, CEO and co-founder of Recursion, expressed enthusiasm about Dr. Hershberg's appointment, particularly in light of the company's pipeline and clinical trials. Gibson also extended gratitude to Martin Chavez, the outgoing chair, for his guidance and mentorship.

Martin Chavez, the departing chair, lauded Recursion's leadership in the "techbio" space, emphasizing the company's pivotal role in revolutionizing the biopharma industry. He expressed confidence in Dr. Hershberg's ability to lead the board through the next chapter, especially as multiple clinical readouts are anticipated.

Recursion, a clinical-stage techbio company, operates at the intersection of technology and biology to advance drug discovery. The company's proprietary biological and chemical datasets, combined with sophisticated machine-learning algorithms, enable the extraction of trillions of searchable relationships across biology and chemistry. Recursion's massive experimental and computational scale positions it as a leader in leveraging technology, biology, and chemistry to shape the future of medicine.

Headquartered in Salt Lake City, Recursion is a founding member of BioHive, the Utah life sciences industry collective, with additional offices in Toronto, Montréal, and the San Francisco Bay Area.

For more information on Recursion, visit www.recursion.com, or connect on Twitter and LinkedIn. As a result of these announcements, the company's shares have moved 1.4% on the market, and are now trading at a price of $9.16. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS